Bots, editor, reviewer, Administrators
13,941
edits
WikiJournalClub:High-priority articles: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
===Incomplete or nonexistent=== | ===Incomplete or nonexistent=== | ||
* 2025 {{create article link|SURMOUNT-5}}: Tirzepatide vs. semaglutide for obesity [https://www.nejm.org/doi/full/10.1056/NEJMoa2416394] | |||
* 2025 {{create article link|OPTION}}: AF ablation followed by LAA closure vs. anticoagulation [https://www.nejm.org/doi/full/10.1056/NEJMoa2408308] | * 2025 {{create article link|OPTION}}: AF ablation followed by LAA closure vs. anticoagulation [https://www.nejm.org/doi/full/10.1056/NEJMoa2408308] | ||
* 2025 {{create article link|Advance-HTN}}: Lorundrostat (aldosterone synthase inhibitor) for uncontrolled HTN [https://www.nejm.org/doi/full/10.1056/NEJMoa2501440] | * 2025 {{create article link|Advance-HTN}}: Lorundrostat (aldosterone synthase inhibitor) for uncontrolled HTN [https://www.nejm.org/doi/full/10.1056/NEJMoa2501440] | ||
* 2025 {{create article link|API-CAT}}: Full vs. reduced dose apixaban for cancer-associated VTE secondary prevention [https://www.nejm.org/doi/full/10.1056/NEJMoa2416112] | * 2025 {{create article link|API-CAT}}: Full vs. reduced dose apixaban for cancer-associated VTE secondary prevention [https://www.nejm.org/doi/full/10.1056/NEJMoa2416112] | ||
* 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | * 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | ||